Kuros Biosciences’ released its MagnetOS minimally invasive spine delivery system in a full commercial launch.
MagnetOS is a bone graft delivery system and is sterile, prefilled, free of human tissue and has a mechanism of action backed by Level I clinical evidence.
“The launch of MagnetOs MIS is more than a product milestone – it reflects our vision to redefine what’s possible in spine surgery,” Chris Fair, CEO of Kuros, said in a Sept. 30 news release. “By combining efficiency, precision, and the strength of Level I clinical evidence, we’re setting a new standard for minimally invasive care. At Kuros, our mission is to empower surgeons with innovations that don’t just keep pace with the future of surgery but help shape it.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
